Squarepoint
HOWL icon

Squarepoint’s Werewolf Therapeutics HOWL Stock Holding History

Squarepoint’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.2K Buy
+103,242
New +$62.9K ﹤0.01% 4284
2025
Q2 		– Sell
-11,828
Closed -$11.5K – 4723
2025
Q1 		$11.5K Buy
+11,828
New +$15.5K ﹤0.01% 4459
2024
Q2 		– Sell
-24,594
Closed -$159K – 4311
2024
Q1 		$159K Buy
+24,594
New +$143K ﹤0.01% 3686

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
VA
Verdad Advisers Boston, Massachusetts $104M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Squarepoint's HOWL Position: Q2 2026 in Review

Squarepoint opened a new position in Werewolf Therapeutics (HOWL) in Q2 2026: 103,242 shares worth $37.2K. The stake represents ﹤0.01% of the portfolio and ranks #4284 among its holdings. This is a return to the name: Squarepoint previously reported a position in HOWL as recently as Q1 2025.

Squarepoint first reported a position in HOWL in Q1 2024 and has held it in 3 quarters since. The position peaked at $159K in Q1 2024. 45 funds tracked by Wall St. Rank hold HOWL as of Q2 2026.

  • Squarepoint held 103,242 shares of Werewolf Therapeutics worth $37.2K as of Q2 2026.
  • Werewolf Therapeutics was a new Squarepoint position in Q2 2026.
  • Werewolf Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #4284 holding.
  • Squarepoint first reported a position in Werewolf Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • Squarepoint's Werewolf Therapeutics position peaked at $159K in Q1 2024.
  • 45 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.